Literature DB >> 29348179

Cigarette smoking and response to inhaled corticosteroids in COPD.

Surya P Bhatt1, Julie A Anderson2, Robert D Brook3, Peter M A Calverley4, Bartolome R Celli5, Nicholas J Cowans6, Courtney Crim7, Fernando J Martinez8, David E Newby9, Jørgen Vestbo10, Julie C Yates7, Mark T Dransfield11,12.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 29348179     DOI: 10.1183/13993003.01393-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  6 in total

1.  Pulmonary Function Changes in Chronic Obstructive Pulmonary Disease Patients According to Smoking Status.

Authors:  Aşkın Gülşen
Journal:  Turk Thorac J       Date:  2020-03-01

2.  Impact of smoking status on the efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review.

Authors:  Kimberley Sonnex; Hanna Alleemudder; Roger Knaggs
Journal:  BMJ Open       Date:  2020-04-15       Impact factor: 2.692

3.  Triple therapy for COPD: a crude analysis from a systematic review of the evidence.

Authors:  Jose Luis Lopez-Campos; Laura Carrasco-Hernandez; Esther Quintana-Gallego; Carmen Calero-Acuña; Eduardo Márquez-Martín; Francisco Ortega-Ruiz; Joan B Soriano
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

4.  Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials.

Authors:  David M G Halpin; Claus F Vogelmeier; Karen Mezzi; Pritam Gupta; Konstantinos Kostikas; Jadwiga A Wedzicha
Journal:  ERJ Open Res       Date:  2021-02-22

Review 5.  Asthma and Tobacco Smoking.

Authors:  Vanesa Bellou; Athena Gogali; Konstantinos Kostikas
Journal:  J Pers Med       Date:  2022-07-27

6.  Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial.

Authors:  Leif H Bjermer; Isabelle H Boucot; Claus F Vogelmeier; François Maltais; Paul W Jones; Lee Tombs; Chris Compton; David A Lipson; Edward M Kerwin
Journal:  Adv Ther       Date:  2021-08-04       Impact factor: 3.845

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.